Monivent signs MOU with American Academy of Pediatrics

Monivent AB announces today that the company has signed a Memorandum of Understanding (MOU) together with the American Academy of Pediatrics, AAP, an organization of over 67,000 pediatricians committed to improving the health of all infants and adolescents. This MOU states that the two organizations wish to establish a strategic alliance with the primary purpose of advancing the health and welfare for children and their families and to collaborate in areas of mutual interest that benefits this purpose. 

As part of the common mission of improving newborn health, one aim is to use Monivent’s monitoring technology to gather ventilation data during newborn resuscitation at hospitals associated with the multi-center Delivery Room Intervention and Evaluation (DRIVE) Network. This network was convened by the AAP to study neonatal resuscitation practices and includes a number of academic centers across the United States.

“We are very excited about the opportunity to collaborate with the AAP and support the important research within the DRIVE Network. Being able to contribute to the common goal of improving health of all newborns is completely in line with Monivent's vision. This alliance will also provide us with the opportunity to create a deeper customer understanding even before Neo100 is cleared by the FDA”, says Karin Dahllöf, CEO of Monivent.

For more information, please contact:
Karin Dahllöf, CEO
Phone: +46 70 748 01 30
E-mail: karin@monivent.se
Website: www.monivent.se

The American Academy of Pediatrics (AAP), is a professional organization comprised of over 67,000 pediatricians and pediatric subspecialists. The mission of the AAP is to attain optimal physical, mental, and social health and well-being for all infants, children, adolescents, and young adults.

Monivent AB (“Monivent”) develops, manufactures and sells medical devices in order to improve the emergency care provided to newborns in need of respiratory support at birth. About three to six percent of all newborns end up in this critical situation and healthcare professionals today lack good tools to determine how effective this manual ventilation is. Monivent has developed equipment that measures the airflow to the child directly in the face mask via a sensor module that sends data wirelessly to an external monitor. The caregiver thereby receives immediate feedback, which enables necessary adjustments to support an effective but at the same time gentle treatment. The company is also marketing a product for simulation based training on manikins, building on the same technology as the clinical product. The clinical product, Monivent Neo100, is not available for sale in the United States.